Cargando…

1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?

BACKGROUND: Common operational definitions of antibiotic exposures in infectious diseases research do not accurately reflect actual treatment, as daily changes in clinical presentation (i.e. improvement, worsening) and clinical information (i.e. causative organism, susceptibilities) lead to frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Caffrey, Aisling, Lopes, Vrishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777992/
http://dx.doi.org/10.1093/ofid/ofaa439.1810
_version_ 1783631033282854912
author Caffrey, Aisling
Lopes, Vrishali
author_facet Caffrey, Aisling
Lopes, Vrishali
author_sort Caffrey, Aisling
collection PubMed
description BACKGROUND: Common operational definitions of antibiotic exposures in infectious diseases research do not accurately reflect actual treatment, as daily changes in clinical presentation (i.e. improvement, worsening) and clinical information (i.e. causative organism, susceptibilities) lead to frequent changes in treatment, both within empiric and definitive treatment periods. Common definitions create periods of ‘ignored’ exposures, and we’ve previously shown that antibiotic treatments during ‘ignored’ periods vary widely. Therefore, we assessed the distribution of important time points for antibiotic treatments for Staphylococcus aureus bacteremia. METHODS: Our retrospective cohort study included hospital admissions in the national Veterans Affairs (VA) Healthcare System with S. aureus positive blood cultures from 2010 to 2018. Admissions with inappropriate initial antibiotic therapy for S. aureus were excluded. We implemented daily exposure mapping to identify antibiotic exposures and changes in treatment on each day of the admission until discharge, or 30 days post-admission for longer stays, and in relation to the culture final report date. RESULTS: We identified 21,947 admissions meeting our inclusion criteria. Antibiotic initiation most often occurred on the culture collection date (68.7%) or the day after (22.6%). Median time to the culture final report date from the culture collection date was 4 days (interquartile range [IQR] 3 to 5). Among those with changes in therapy (n=19,392, 88.4%), median time to first change in therapy was 2 days prior to the culture final report date (IQR -3 to -1). The first change in therapy occurred before the culture final report date for 76.3% of admissions and on the culture final report date for 11.9% of admissions. Further changes were common on the culture final report date (49.5%) and the day after the final report date (45.3%). CONCLUSION: Changes in antibiotic therapy are common prior to finalization of culture reports. While initial culture results and provider knowledge of these initial results are not date/time-stamped, initial change within a reasonable period from culture collection appears to be more accurate in defining empiric and definitive treatment periods than commonly used operational definitions. DISCLOSURES: Aisling Caffrey, PhD, Merck (Research Grant or Support)Pfizer (Research Grant or Support)Shionogi (Research Grant or Support)
format Online
Article
Text
id pubmed-7777992
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77779922021-01-07 1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia? Caffrey, Aisling Lopes, Vrishali Open Forum Infect Dis Poster Abstracts BACKGROUND: Common operational definitions of antibiotic exposures in infectious diseases research do not accurately reflect actual treatment, as daily changes in clinical presentation (i.e. improvement, worsening) and clinical information (i.e. causative organism, susceptibilities) lead to frequent changes in treatment, both within empiric and definitive treatment periods. Common definitions create periods of ‘ignored’ exposures, and we’ve previously shown that antibiotic treatments during ‘ignored’ periods vary widely. Therefore, we assessed the distribution of important time points for antibiotic treatments for Staphylococcus aureus bacteremia. METHODS: Our retrospective cohort study included hospital admissions in the national Veterans Affairs (VA) Healthcare System with S. aureus positive blood cultures from 2010 to 2018. Admissions with inappropriate initial antibiotic therapy for S. aureus were excluded. We implemented daily exposure mapping to identify antibiotic exposures and changes in treatment on each day of the admission until discharge, or 30 days post-admission for longer stays, and in relation to the culture final report date. RESULTS: We identified 21,947 admissions meeting our inclusion criteria. Antibiotic initiation most often occurred on the culture collection date (68.7%) or the day after (22.6%). Median time to the culture final report date from the culture collection date was 4 days (interquartile range [IQR] 3 to 5). Among those with changes in therapy (n=19,392, 88.4%), median time to first change in therapy was 2 days prior to the culture final report date (IQR -3 to -1). The first change in therapy occurred before the culture final report date for 76.3% of admissions and on the culture final report date for 11.9% of admissions. Further changes were common on the culture final report date (49.5%) and the day after the final report date (45.3%). CONCLUSION: Changes in antibiotic therapy are common prior to finalization of culture reports. While initial culture results and provider knowledge of these initial results are not date/time-stamped, initial change within a reasonable period from culture collection appears to be more accurate in defining empiric and definitive treatment periods than commonly used operational definitions. DISCLOSURES: Aisling Caffrey, PhD, Merck (Research Grant or Support)Pfizer (Research Grant or Support)Shionogi (Research Grant or Support) Oxford University Press 2020-12-31 /pmc/articles/PMC7777992/ http://dx.doi.org/10.1093/ofid/ofaa439.1810 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Caffrey, Aisling
Lopes, Vrishali
1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
title 1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
title_full 1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
title_fullStr 1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
title_full_unstemmed 1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
title_short 1630. What is Treatment Time Zero Among Hospitalized Patients with Bacteremia?
title_sort 1630. what is treatment time zero among hospitalized patients with bacteremia?
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777992/
http://dx.doi.org/10.1093/ofid/ofaa439.1810
work_keys_str_mv AT caffreyaisling 1630whatistreatmenttimezeroamonghospitalizedpatientswithbacteremia
AT lopesvrishali 1630whatistreatmenttimezeroamonghospitalizedpatientswithbacteremia